Glutathione and Parkinson's disease: Is this the elephant in the room?

Biomedicine and Pharmacotherapy

Volumn 62, Issue 4, 2008, Pages 236-249

  Zeevalk, Gail D ^a   Razmpour, Roozbeh ^b   Bernard, Laura P ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Glutathione; Parkinson's disease; Therapeutics

Indexed keywords

AMINO ACID; DNA; GLUTAMATE RECEPTOR; GLUTATHIONE; HYDROGEN PEROXIDE; LIPID; PROTEIN;

AMINO ACID TRANSPORT; ANTIOXIDANT ACTIVITY; ARTICLE; DIFFUSE LEWY BODY DISEASE; DNA REPAIR; DNA SYNTHESIS; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REACTION ANALYSIS; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; DIPEPTIDES; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE; HUMANS; PARKINSON DISEASE;

EID: 43049145863     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.01.017     Document Type: Article

References (137)

1. Del Tredici K., Rub U., De Vos R.A.I., Bohl J.R.E., and Braak H. Where does Parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 61 5 (2002) 413
2. Tan E.K., and Skipper L.M. Pathogenic mutations in Parkinson disease. Hum Mutat 28 7 (2007) 641
3. Abeliovich A., and Beal M.F. Parkinsonism genes: culprits and clues. J Neurochem 99 4 (2006) 1062
4. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9 (1994) 92
5. Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P., and Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's disease but not incidental Lewy body disease. J Neurochem 69 (1997) 1326
6. Beal M.F. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32 9 (2002) 797
7. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., et al. Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxy-guanine in substantia nigra?. J Neurochem 69 (1997) 1196
8. Sanchez-Ramos J., Overvik E., and Ames B.N. A marker of oxyradical-mediated DNA damage [8-hydroxy-2′-deoxyguanosine] is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197
9. Parker W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719
10. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Complex I deficiency in Parkinson's disease. J Neurochem 54 (1990) 823
11. Haas R.H., Nasirian F., Nakano K., Ward D., Pay R.N., Hill R., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's Disease. Ann Neurol 37 (1995) 714
12. Mizuno Y., Matsuda S., Yoshino H., Mori H., Hattori N., and Ikebe S.I. An immunohistochemical study on αketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35 (1994) 204
13. Benecke R., Strumper P., and Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116 (1993) 1451
14. McNaught K.S., Jackson T., JnoBaptiste R., Kapustin A., and Olanow C.W. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 66 10 (2006) S37
15. Perry T., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci Lett 33 (1982) 305
16. Jenner P., Dexter D.T., Sian J., Schapira A.H.V., and Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 32 (1992) S82
17. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52 (1989) 515
18. Pearce R.K.B., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104 (1997) 661
19. Cooper A.J.L., and Kristal B.S. Multiple roles of glutathione in the central nervous system. Biol Chem 378 (2007) 793
20. Rice M.E., and Russo-Menna I. Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 82 4 (1998) 1213
21. Philbert M.A., Beiswanger C.M., Waters D.K., Reuhl K.R., and Lowndes H.E. Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-pthaldialdehyde-induced histofluorescence. Toxicol Appl Pharmacol 107 (1991) 215
22. Saez G.T., Bannister W.H., and Bannister J.V. Free radicals and thiol compounds - the role of glutathione against free radical toxicity. In: Vina J. (Ed). Glutathione: metabolism and physiological functions (1990), CRC Press, Boca Raton, FL, USA 237
23. Clancy R.M., Lavartovsky D., Leszcynska-Piziak J., Yegudin J., and Abramson S.B. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediate. Proc Natl Acad Sci U S A 91 (1994) 3680
24. Winterbourn C.C., and Metodiewa D. The reactions of superoxide with reduced glutathione. Arch Biochem Biophys 314 (1994) 284
25. Bains J.S., and Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 25 (1997) 335
26. Wullner U., Loschmann P.A., Schulz J.B., Schmid A., Dringen R., Eblen F., et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. NeuroReport 7 (1996) 921
27. Zeevalk G.D., Bernard L.P., Albers D.S., Mirochnitchenko O., Nicklas W.J., and Sonsalla P.K. Energy stress-induced dopamine loss in glutathione peroxidase-overexpressing transgenic mice and in glutathione-depleted mesencephalic cultures. J Neurochem 68 (1997) 426
28. Zeevalk G.D., Bernard L.P., and Nicklas W.J. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. J Neurochem 70 (1998) 1421
29. Klivenyi P., Andreassen O.A., Ferrante R.J., Dedeoglu A., Mueller G., Lancelot E., et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitopropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 20 (2000) 1
30. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., and LeCouteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 9137 (1998) 1344
31. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in alpha synuclein identified in families with Parkinson's disease. Science 276 (1997) 2045
32. Golbe L.I., Di Iorio G., Markopoulou K., Athanassiadou A., Papapetropoulos S., Watts R.L., et al. Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. Am J Med Gen 144 (2007) 254
33. Dalla-Donne I., Rossi R., Giustarini D., Colombo R., and Milzani A. S-glutathionylation in protein redox regulation. Free Radic Biol Med 43 (2007) 883
34. Manevich Y., and Fisher A.B. Peroxiredoxin 6, a 1-cysperoxidredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 38 (2005) 1422
35. Wells W.W., Yang Y., and Deits T.L. Thioltransferases. Adv Enzymol Relat Areas Mol Biol 66 (1993) 149
36. Mieyal J.J., Srinivasan U., Starke D.W., Gravina S.A., and Mieyal P. Glutathionyl specificity of thioltransferases: mechanistic and physiological implication. In: Packer L.C.E. (Ed). Biothiols in health and disease (1995), Marcel Decker, New York 305
37. Jung C.-H., and Thomas J.A. S-glutathiolated hepatocyte proteins and insulin disulfides as substrates for reduction by glutaredoxin, thioredoxin, protein disulfide isomerase and glutathione. Arch Biochem Biophys 335 1 (1996) 61
38. Balijepalli S., Tirumalai P.S., Swamy K.V., Boyd M.R., Mieyal J.J., and Ravindranath V. Rat brain thioltransferase: regional distribution, immunological characterization, and localization by fluorescent in situ hybridization. J Neurochem 72 (1999) 1170
39. Ehrhart J., Gluck M., Mieyal J., and Zeevalk G.D. Functional glutaredoxin [thioltransferase] activity in rat brain and liver mitochondria. Parkinsonism Relat Disord 8 6 (2002) 395
40. Balijepalli S., Boyd M.R., and Ravindranath V. Human brain thioltransferase: constitutive expression and localization by fluorescence in situ hybridization. Brain Res 85 1-2 (2000) 123
41. Wells W.W., Xu D.P., Yang Y., and Rocque P.A. Mammalian thioltransferase [glutaredoxin] and protein disulfide isomerase have dehydroascorbate reductase activity. J Biol Chem 265 26 (1990) 15361
42. Fernando M.R., Satake M., Monnier V.M., and Lou M.F. Thioltransferase mediated ascorbate recycling in human lens epithelial cells. Invest Ophthalmol Vis Sci 45 1 (2004) 230
43. Ehrhart J., and Zeevalk G.D. Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. J Neurochem 77 (2001) 1496
44. Ehrhart J., and Zeevalk G.D. Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J Neurochem 86 (2003) 1487
45. Zeevalk G.D., Bernard L.P., and Ehrhart J. Glutathione and ascorbate: role in protein-glutathione-mixed disulfide formation during oxidative stress and potential relevance to Parkinson's disease. Ann N Y Acad Sci 991 (2003) 342
46. Wang J., Boja E.S., Tan W.H., Tekle E., Fales H.M., English S., et al. Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 276 (2001) 47763
47. Starke D.W., Chock P.B., and Mieyal J.J. Glutathione-thiyl radical scavenging and transferase properties of human glutaredoxin [thioltransferase] - potential role in redox signal transduction. J Biol Chem 278 17 (2003) 14607
48. Janaky R., Ogita K., Pasqualotto B.A., Bains J.S., Oja S.S., Yondea Y., et al. Glutathione and signal transduction in the mammalian CNS. J Neurochem 73 (1999) 889
49. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 62 (2000) 649
50. Makar T.K., Nedergaard M., Preuss A., Gelbard A.S., Perumal A.S., and Cooper A.J.L. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J Neurochem 62 (1994) 45
51. Misra I., and Griffith O.W. Expression and purification of human gamma-glutamylcysteine synthetase. Protein Expr Purif 13 (1998) 268
52. Shine H.D., and Haber B. Immunocytochemical localization of gamma-glutamyl transpeptidase in the rat CNS. Brain Res 217 (1981) 339
53. Philbert M.A., Beiswanger C.M., Manson M.M., Green J.A., Novak R.F., Primiano T., et al. Glutathione-S-transferases and gamma-glutamyl transpeptidase in the rat nervous system: a basis for differential susceptibility to neurotoxicants. Neurotoxicology 16 (1995) 349
54. Tate S.S. In: Jakoby W.B. (Ed). Enzymatic basis of detoxication (1980), Academic Press 95
55. Dringen R., Pfeiffer B., and Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19 (1999) 562
56. Sagara J., Miura K., and Bannai S. Maintenance of neuronal glutathione by glial cells. J Neurochem 61 (1993) 1677
57. Sagara J., Miura K., and Bannai S. Cystine uptake and glutathione level in fetal brain cells in primary culture and in suspension. J Neurochem 61 (1993) 1667
58. Sagara J., Makino N., and Bannai S. Glutathione efflux from cultured astrocytes. J Neurochem 66 (1996) 1876
59. Yudkoff M., Pleasure D., Cregar L., Lin Z.-P., Nissim I., and Stern N.I. Glutathione turnover in cultured astrocytes: studies with [15N] glutamate. J Neurochem 55 (1990) 137
60. Dringen R., Kranich O., and Hamprecht B. The gamma-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture. Neurochem Res 22 6 (1997) 727
61. Dringen R., Kranich O., Loschmann P.A., and Hamprecht B. Use of dipeptides for the synthesis of glutathione by astroglia-rich primary cultures. J Neurochem 69 (1997) 868
62. Perry T.L., and Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67 (1986) 269
63. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36 (1994) 348
64. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142 (1992) 128
65. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., and Marsden C.D. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36 (1994) 356
66. Gibb W.R.G., and Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 51 6 (1988) 745
67. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 (2003) S26
68. Avraham E., Szargel R., Eyal A., Rott R., and Engelender S. Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J Biol Chem 280 52 (2005) 42877
69. Lee M.H., Hyun D.H., Jenner P., and Halliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem 78 (2001) 32
70. Gispert-Sanchez S., and Auburger G. The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?. J Neural Transm Suppl 70 (2006) 111
71. Harrower T.P., Michell A.W., and Barker R.A. Lewy bodies in Parkinson's disease: protectors or perpetrators?. Exp Neurol 195 1 (2005) 1
72. Jenner P., Schapira A.H.V., and Marsden C.D. New insights into the cause of Parkinson's disease. Neurology 42 (1992) 2241
73. Shoffner J.M., Watts R.L., Juncos J.L., Torroni A., and Wallace D.C. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30 (1991) 332
74. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schapira A.H.V., and Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 (1992) 333
75. Bindoff L.A., Birch-Machin M.A., Cartidge N.E.F., Parker W.D., and Turnbull D.M. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 104 (1991) 203
76. Schapira A.H.V., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., et al. Anatomic and disease specificity of NADH CoQ reductase (complexI) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142
77. Chinta S.J., and Andersen J.K. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 41 9 (2006) 1442
78. Vesce S., Jekabsons M.B., Johnson-Cadwell L.I., and Nicholls D.G. Acute glutathione depletion restricts mitochondrial ATP export in cerebellar granule neurons. J Biol Chem 280 46 (2005) 38720
79. Zhang J., Kravtsov V., Amarnath V., Picklo M.J., Graham D.G., and Montine T.J. Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. J Neurochem 74 (2000) 970
80. Vyas I., Heikkila R.E., and Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 46 (1986) 1501
81. Riederer P., Strolin B.M., Dostert P., Sofic E., Heusch-neider G., and Guffroy D. Do glutathione and ascorbic acid play a role in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine?. Pharmacol Toxicol 60 S1 (1987) 39
82. Chang M.L., Klaidman L.K., and Adams Jr. J.D. The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice. Mol Chem Neuropathol 30 3 (1997) 187
83. Neafsey E.J., Drucker G., Raikoff K., and Collins M.A. Striatal dopaminergic toxicity following intranigral injection in rats of 2-methyl-norharman, a B-carbolinium analog of n-methyl-4-phenylpyridinium ion. [MPP+]. Neurosci Lett 105 (1989) 344
84. Collins M.A., and Neafsey E.J. B-carboline analogues of n-methyl-4-phenyl-1,2,5,6-tetrahydropyridine [MPTP]: endogenous factors underlying idiopathic parkinsonism?. Neurosci Lett 55 (1985) 179
85. Perry T.L., Jone K., Hansen S., and Wall R.A. 4-Phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: lack of dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Neurosci Lett 75 (1987) 65
86. Hastings T.G., Lewis D.A., and Zigmond M.J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387 (1996) 97
87. Moy L.Y., Zeevalk G.D., and Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J Neurochem 74 (2000) 1656
88. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14 (1978) 633
89. Zhang F., and Dryhurst G. Effects of l-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37 8 (1994) 1084
90. Spencer P.E., Jenner P., Daniel S.E., Lees A.J., Marsden C.D., and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71 (1998) 2112
91. Carlsson A., and Fornstedt B. Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 41 5 (1991) 50
92. Cheng F.C., Kuo J.S., Chia L.G., and Dryhurst G. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm 103 4 (1996) 433
93. Skaper S.D., Fabris M., Ferrari V., Dalle Carbonare M., and Leon A. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. Free Radic Biol Med 22 4 (1997) 669
94. Mytilineou C., Cramer B.C., and Yabut J.A. Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 8 6 (2002) 385
95. Papa L., Gomes E., and Rockwell P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis 12 8 (2007) 1389
96. Yamamoto N., Sawada H., Izumi Y., Kumd T., Katsuki H., Shimohama S., et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 282 (2007) 4364
97. Bharath S., and Andersen J.K. Glutathione depletion in a midbrain-derived immortalized dopaminergic cell line results in limited tyrosine nitration of mitochondrial complex I subunits: implications for Parkinson's disease. Antioxid Redox Signal 7 7-8 (2005) 900
98. Gupta A., Gupta A., Datta M., and Shukla G.S. Cerebral antioxidant status and free radical generation following glutathione depletion and subsequent recovery. Mol Cell Biochem 209 1-2 (2000) 55
99. Lash L.H. Role of glutathione transport processes in kidney function. Toxicol Appl Pharmacol 204 3 (2005) 329
100. In: Dolphin D., Poulson R., and Avramovic O. (Eds). Glutathione: chemical, biochemical and medical aspects (1989), Wiley, New York 22
101. Zeevalk G.D., Manzino L., Sonsalla P.K., and Bernard L.P. Characterization of intracellular elevation of glutathione [GSH] with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203 2 (2007) 512
102. Kannan R., Kuhlenkamp J.F., Jeandidler E., Trinh H., Ookhtens M., and Kkaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood brain barrier in the rat. J Clin Invest 85 (1990) 2009
103. Cornford E.M., Braun L.D., Crane P.D., and Oldendorf W.H. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 103 4 (1978) 1297
104. Pileblad E., and Magnusson T. Increase in rat-brain glutathione following intracerebroventricular administration of gamma-glutamylcysteine. Biochem Pharmacol 44 5 (1992) 895
105. Testa R., Ghia M., Mattioli F., Borzone S., Caglieris S., Mereto E., et al. Effects of reduced glutathione and N-acetylcysteine on likocaine metabolism in cimetidine treated rats. Fund & Clin Pharmacol 12 (1998) 220
106. Gillissen A., Joworska M., Orth M., Coffiner M., Maes P., App E.M., et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respiratory Medicine 91 (2006) 159
107. Pocernich C.B., Cardin A.L., Racine C.L., Lauderback C.M., and Butterfield D.A. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39 (2001) 141
108. Pocernich C.B., LaFontaine M., and Butterfield D.A. In vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int 36 (2000) 185
109. McLellan L., Lewis A.D., Hall D.J., Ansell J.D., and Wolf C.R. Uptake and distribution of N-acetylcysteine in mice: tissue specific effects on glutathione concentrations. Carcinogenesis 16 (1995) 2099
110. Wade L.A., and Brady H.M. Cysteine and cystine transport at the blood-brain barrier. J Neurochem 37 (1981) 730
111. Olney J.W., Zorumski C., Price M.T., and Labruyere J. l-cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science 248 4955 (1990) 596
112. Puka-Sundvall M., Eriksson P., Nilsson M., Sandberg M., and Lehmann A. Neurotoxicity of cysteine: interaction with glutamate. Brain Res 705 1-2 (1995) 65
113. Munoz A.M., Rey P., Soto-Otero R., Guerra M.J., and Labandeira-Garcia J.L. Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J Neurosci Res 76 4 (2004) 551
114. Martensson J., and Meister A. Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Sci U S A 86 (1989) 471
115. Anderson M.F., Nilsson M., and Sims N.R. Glutathione monoethylester prevents mitochondrial glutathione depletion during focal cerebral ischemia. Neurochem Int 44 3 (2004) 153
116. Anderson M.F., and Sims N.R. The effects of focal ischemia and reperfusion on the glutathione content of mitochondria from rat brain subregions. J Neurochem 81 (2002) 541
117. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 Suppl (1992) S128
118. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 44 3 Suppl 1 (1998) S160
119. Shults C.W., Haas R.H., Passov D., and Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42 (1997) 261
120. Storch A., Jost W.H., Vieregge P., Spiegel J., Greulich W., Durner J., et al. Randomized double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64 (2007) 938
121. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuro-Psychopharmacol Biol Psychiat 20 (1996) 1159
122. Magnani M., Novelli G., and Palloni R. Human plasma glutathione oxidation in normal and pathological conditions. Clin Physiol Biochem 2 (1984) 287
123. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AVV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097
124. Iwata-Ichikawa E., Kondo Y., Miyazaki I., Asanuma M., and Ogawa N. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J Neurochem 72 6 (1999) 2334
125. Shih A.Y., Johnson D.A., Wong G., Kraft A.D., Jiang L., Erb H., et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23 (2003) 3394
126. Nagashima R., and Ogita K. Enhanced biosynthesis of glutathione in the spiral ganglion of the cochlea after in vivo treatment with dexamethasone in mice. Brain Res 1117 1 (2006) 101
127. Regan R.F., and Guo Y.P. Potentiation of excitotoxic injury by high concentrations of extracellular reduced glutathione. Neuroscience 91 2 (1999) 463
128. Regan R., and Guo Y. Extracellular reduced glutathione increases neuronal vulnerability to combined chemical hypoxia and glucose deprivation. Brain Res 817 (1999) 145
129. Dringen R., Hamprecht B., and Broer S. The peptide transporter PepT2 mediates the uptake of the glutathione precursor CysGly in astroglia-rich primary cultures. J Neurochem 71 (1998) 388
130. Tom Dieck S., Heuer H., Ehrchen J., Otto C., and Bauer K. The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative B-Ala-Lys-N-AMCA in astrocytes. Glia 25 (1999) 10
131. Morris J., and Leslie S.W. Glutamate and cysteinylglycine effects on NMDA receptors: inhibition by ethanol. Alcohol 13 2 (1996) 157
132. Zhao K., Luo G., Zhao G.-M., Schiller P.W., and Szeto H.H. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther 304 1 (2003) 425
133. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47 (2001) 65
134. Schroeder U., Sommerfeld P., Ulrich S., and Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87 (1998) 1305
135. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles. [nanoparticles]. Brain Res 674 (1995) 171
136. Zeevalk G.D., Derr-Yellin E., and Nicklas W.J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J Pharmacol Exp Ther 275 (1995) 1124
137. Zeevalk G.D., Bernard L.P., and Nicklas W.J. Oxidative stress during energy impairment in mesencephalic cultures is not a downstream consequence of a secondary excitotoxicity. Neuroscience 96 2 (2000) 309